News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

November 24, 2020

Category

Partner News

Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin

Published

October 29, 2020

Category

PARI News

LAMIRA®, an eFlow® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union

Published

October 22, 2020

Category

PARI News

PARI's optimized Investigational eFlow® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial

Published

October 16, 2020

Category

Partner News

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial

Published

October 13, 2020

Category

Partner News

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team